Lavinia D. B.
- Country
- Romania
- Department
- Pneumologie
Research Overview
- A Phase 2a Study to Evaluate the Safety and Efficacy of ABBV-142 in Adults with Idiopathic Pulmonary Fibrosis
- Phase 3 Study of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
- Evaluation of Axatilimab Efficacy, Safety, and Tolerability in Idiopathic Pulmonary Fibrosis: A 26-Week Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 33 of 186 partner sites.
Specializations
Idiopathic Pulmonary Fibrosis
Clinical research activity includes the evaluation of investigational therapies for idiopathic pulmonary fibrosis, with attention to lung function, disease activity, and treatment safety in adult patients.
- Idiopathic pulmonary fibrosis
- Lung function preservation
- Therapeutic safety and tolerability
The work also reflects interest in antifibrotic treatment strategies and emerging options for progressive interstitial lung disease.
Chronic Obstructive Pulmonary Disease
Another major focus is chronic obstructive pulmonary disease, including studies centered on symptom control, airflow improvement, and reduction of exacerbation burden in adults with persistent respiratory impairment.
- Chronic obstructive pulmonary disease (COPD)
- Exacerbation prevention
- Triple inhaled therapy
This area includes interest in novel inhaled therapies and biologic approaches for patients with ongoing disease activity despite maintenance treatment.
Asthma
Clinical trial involvement extends to asthma, with emphasis on control of symptoms, improvement of lung function, and management of both mild-to-moderate and severe uncontrolled disease.
- Mild to moderate asthma
- Severe uncontrolled asthma
- Exacerbation reduction
Research interest also covers combination inhaled treatments and adjunctive biologic therapy for patients needing stronger disease control.
Biologic and Targeted Respiratory Therapy
Several studies address biologic therapy and targeted treatment pathways in respiratory disease, particularly for type 2 inflammation and exacerbation-prone airway disorders.
- Type 2 inflammation
- Monoclonal antibody therapy
- Advanced anti-inflammatory strategies
This reflects involvement in therapeutic innovation for patients with chronic inflammatory lung disease who remain symptomatic despite standard care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.